Insight, China's Pharmaceutical Industry

Company Drug

LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment

LEO Pharma A/S has received marketing approval from China’s National Medical Products Administration (NMPA) for...

Company Drug

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

Fineline Cube Apr 20, 2026

The National Medical Products Administration (NMPA) has granted approval to Chia Tai Tianqing Pharmaceutical Co.,...

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026

UCB (EBR: UCB) has agreed to acquire Neurona Therapeutics, a U.S.-based biotechnology company developing NRTX-1001,...

Company Drug

Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors

Fineline Cube Apr 20, 2026

Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) unveiled Phase I clinical trial results for risvutatug...

Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026

Pulnovo Medical, a Chinese pulmonary hypertension (PH) has secured over USD 100 million in an...

Company Drug

Eli Lilly Launches Omvoh (Mirikizumab) in China for Inflammatory Bowel Disease – IL-23p19 Antagonist Targets Ulcerative Colitis and Crohn’s Disease Following February Approval

Fineline Cube Apr 20, 2026

Eli Lilly & Co. (NYSE: LLY) has officially launched Omvoh (mirikizumab) in China for the...

Company Deals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Fineline Cube Apr 20, 2026

SenseTime, a leading Chinese smart diagnosis and treatment solution provider, has completed its Series A...

Company Drug

Kanghong Pharmaceutical Receives FDA Clearance for KHN921 Gene Therapy Trial in MYBPC3-Associated Hypertrophic Cardiomyopathy – Precision AAV Vector Targets Myocardial Tissue

Fineline Cube Apr 20, 2026

Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) announced it has received Investigational New Drug...

Company Deals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Fineline Cube Apr 20, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) successfully completed its initial public offering...

Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Fineline Cube Apr 20, 2026

The National Medical Products Administration (NMPA) this week released the draft proposal “Appendix to the...

Company Drug

Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026

Fineline Cube Apr 20, 2026

Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) unveiled pivotal Phase III DIAMOND-2 trial results for Xuanfeining...

Company Drug

Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026

Fineline Cube Apr 20, 2026

Sino Biopharmaceutical Ltd (HKG: 1177) presented preliminary clinical data for LM-299/MK-2010, a PD-1/VEGF bispecific antibody...

Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026

Eli Lilly & Co. (NYSE: LLY) is reportedly engaged in advanced negotiations to acquire Kelonia...

Company Deals

AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products

Fineline Cube Apr 17, 2026

AbbVie Inc. (NYSE: ABBV), the US pharmaceutical giant, has announced a strategic partnership with the...

Company Deals

Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform

Fineline Cube Apr 17, 2026

Annoroad Gene Technology (Beijing) Co., Ltd., a leading Chinese provider of integrated life science sequencing...

Company Deals

Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu

Fineline Cube Apr 17, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a new licensing agreement with a...

Company Drug

Sunshine Lake Pharma Secures NMPA Approval for In-House Developed Premixed Insulin 30R Prefilled Pen

Fineline Cube Apr 17, 2026

Sunshine Lake Pharma Co., Ltd. (HKG: 6887) announced that its in-house developed isophane protamine recombinant...

Company Drug

Hansoh Pharma’s B7-H3 ADC HS-20093 Secures Fourth NMPA Breakthrough Therapy Designation for NSCLC Combination Therapy

Fineline Cube Apr 17, 2026

Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) has announced that its investigational antibody-drug conjugate (ADC),...

Company Drug

Hengrui Pharma’s Nectin-4 ADC SHR-A2102 Granted Second NMPA Breakthrough Therapy Designation for Cervical Cancer

Fineline Cube Apr 17, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its Category 1 therapeutic...

Company

Abbott Reports 3.8% YOY Revenue Growth in Q1 2026, Led by Diagnostics and Medical Devices

Fineline Cube Apr 17, 2026

Abbott Laboratories (NYSE: ABT) announced its financial results for the first quarter of 2026, reporting...

Insight, China's Pharmaceutical Industry

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Eli Lilly Launches Omvoh (Mirikizumab) in China for Inflammatory Bowel Disease – IL-23p19 Antagonist Targets Ulcerative Colitis and Crohn’s Disease Following February Approval

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Kanghong Pharmaceutical Receives FDA Clearance for KHN921 Gene Therapy Trial in MYBPC3-Associated Hypertrophic Cardiomyopathy – Precision AAV Vector Targets Myocardial Tissue

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026

Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products

Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform

Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu

Sunshine Lake Pharma Secures NMPA Approval for In-House Developed Premixed Insulin 30R Prefilled Pen

Hansoh Pharma’s B7-H3 ADC HS-20093 Secures Fourth NMPA Breakthrough Therapy Designation for NSCLC Combination Therapy

Hengrui Pharma’s Nectin-4 ADC SHR-A2102 Granted Second NMPA Breakthrough Therapy Designation for Cervical Cancer

Abbott Reports 3.8% YOY Revenue Growth in Q1 2026, Led by Diagnostics and Medical Devices

You Missed

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally